![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ache Laboratorios Farmaceuticos SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2023
Details:
Celmatix launches novel pcos program with the potential to expand into the treatment of endometriosis and menopausal symptoms. It is aimed at restoring ovarian function in a way that addresses the root cause of all the symptoms.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
Lead AMHR2 agonist compound demonstrates high specific activity in biological assays and desired pharmacokinetic profile in preclinical animal studies.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Novel PCOS drug target, is largely unknown, genomic studies suggest a strong genetic connection from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2022